Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epithelium, Corneal | 4 | 2009 | 10 | 1.000 |
Why?
|
| Multidrug Resistance-Associated Proteins | 3 | 2009 | 48 | 0.880 |
Why?
|
| Cornea | 2 | 2009 | 58 | 0.610 |
Why?
|
| Patents as Topic | 1 | 2014 | 14 | 0.470 |
Why?
|
| Ophthalmic Solutions | 1 | 2014 | 18 | 0.470 |
Why?
|
| Thiosemicarbazones | 1 | 2012 | 10 | 0.430 |
Why?
|
| Iron Chelating Agents | 1 | 2012 | 21 | 0.430 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 202 | 0.400 |
Why?
|
| Nanoparticles | 2 | 2014 | 318 | 0.400 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 421 | 0.360 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 83 | 0.310 |
Why?
|
| Antiviral Agents | 1 | 2009 | 157 | 0.300 |
Why?
|
| Quinolines | 4 | 2009 | 64 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 213 | 0.290 |
Why?
|
| Eye Proteins | 1 | 2006 | 46 | 0.280 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 284 | 0.270 |
Why?
|
| Membrane Transport Proteins | 1 | 2006 | 95 | 0.270 |
Why?
|
| Pharmaceutical Preparations | 1 | 2006 | 75 | 0.260 |
Why?
|
| Rabbits | 4 | 2010 | 283 | 0.240 |
Why?
|
| Propionates | 3 | 2009 | 26 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1015 | 0.220 |
Why?
|
| Biological Transport | 3 | 2009 | 185 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 623 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 1039 | 0.190 |
Why?
|
| Permeability | 3 | 2010 | 67 | 0.180 |
Why?
|
| Cells, Cultured | 3 | 2009 | 1518 | 0.170 |
Why?
|
| Dogs | 2 | 2009 | 149 | 0.150 |
Why?
|
| Erythromycin | 2 | 2006 | 13 | 0.140 |
Why?
|
| Delayed-Action Preparations | 2 | 2014 | 60 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2009 | 859 | 0.130 |
Why?
|
| Aniline Compounds | 1 | 2015 | 23 | 0.130 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 37 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 112 | 0.120 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 56 | 0.120 |
Why?
|
| Animals | 6 | 2014 | 15081 | 0.120 |
Why?
|
| Cell Line | 2 | 2009 | 1354 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2015 | 82 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 71 | 0.120 |
Why?
|
| Isomerism | 1 | 2012 | 63 | 0.110 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 52 | 0.110 |
Why?
|
| Limit of Detection | 1 | 2012 | 59 | 0.110 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 52 | 0.100 |
Why?
|
| Isoquinolines | 1 | 2012 | 45 | 0.100 |
Why?
|
| Humans | 7 | 2015 | 37093 | 0.100 |
Why?
|
| Iron | 1 | 2012 | 225 | 0.090 |
Why?
|
| Macular Edema | 1 | 2010 | 4 | 0.090 |
Why?
|
| Polyglycolic Acid | 1 | 2010 | 37 | 0.090 |
Why?
|
| Steroids | 1 | 2010 | 43 | 0.090 |
Why?
|
| Cloprostenol | 1 | 2009 | 3 | 0.090 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2009 | 6 | 0.090 |
Why?
|
| Acyclovir | 1 | 2009 | 5 | 0.090 |
Why?
|
| Lactic Acid | 1 | 2010 | 95 | 0.080 |
Why?
|
| Acridines | 1 | 2009 | 1 | 0.080 |
Why?
|
| Acetanilides | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cell Survival | 1 | 2012 | 864 | 0.080 |
Why?
|
| Adenine | 1 | 2009 | 44 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 88 | 0.080 |
Why?
|
| Cell Transformation, Viral | 1 | 2009 | 29 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 935 | 0.080 |
Why?
|
| Drug Resistance, Multiple | 1 | 2009 | 27 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 677 | 0.080 |
Why?
|
| Simian virus 40 | 1 | 2009 | 47 | 0.080 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2009 | 21 | 0.080 |
Why?
|
| Pyrroles | 1 | 2009 | 55 | 0.080 |
Why?
|
| Amides | 1 | 2009 | 68 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 364 | 0.080 |
Why?
|
| Indoles | 1 | 2009 | 158 | 0.070 |
Why?
|
| Ketoconazole | 1 | 2006 | 7 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2006 | 27 | 0.070 |
Why?
|
| Bioprosthesis | 1 | 2005 | 5 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2231 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 18 | 0.070 |
Why?
|
| Aortic Diseases | 1 | 2005 | 27 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 76 | 0.060 |
Why?
|
| Calcinosis | 1 | 2005 | 59 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 149 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2006 | 381 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 130 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2009 | 1207 | 0.060 |
Why?
|
| Gene Expression | 1 | 2006 | 674 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2006 | 384 | 0.060 |
Why?
|
| Proteins | 1 | 2005 | 369 | 0.050 |
Why?
|
| Calcium | 1 | 2005 | 480 | 0.050 |
Why?
|
| Male | 2 | 2009 | 20025 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 83 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2015 | 109 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 444 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2015 | 808 | 0.020 |
Why?
|
| Dialysis | 1 | 2010 | 6 | 0.020 |
Why?
|
| Sclera | 1 | 2010 | 6 | 0.020 |
Why?
|
| Prednisolone | 1 | 2010 | 13 | 0.020 |
Why?
|
| Emulsions | 1 | 2010 | 33 | 0.020 |
Why?
|
| Gels | 1 | 2010 | 42 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2010 | 45 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 86 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2010 | 78 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 286 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 708 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 41 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 32 | 0.020 |
Why?
|